Down regulation of high in normal-1 (HIN-1) is a frequent event in stage I non-small cell lung cancer and correlates with poor clinical outcome - PubMed (original) (raw)

Down regulation of high in normal-1 (HIN-1) is a frequent event in stage I non-small cell lung cancer and correlates with poor clinical outcome

Antonio Marchetti et al. Clin Cancer Res. 2004.

Abstract

Purpose: The aim of this study was to evaluate the prevalence and the clinical significance of HIN-1 mRNA expression in early stage non-small cell lung carcinomas (NSCLCs).

Experimental design: A series of 91 NSCLC patients with stage I neoplastic disease was studied. HIN-1 expression was investigated by quantitative real-time reverse transcription-PCR on tumor specimens and matching normal lung tissues. Variables were analyzed by chi(2) test and Fisher's exact tests. Survival was evaluated with the method of Kaplan-Meier. Multivariate analysis was performed with Cox's proportional hazards model.

Results: Seventy one (78%) tumors showed a reduction of HIN-1 mRNA compared with the normal counterpart. The range of reduction varied greatly, from -2-fold to -3350-fold. Setting a cutoff at -46-fold (median value of HIN-1 mRNA reduction), 46 cases (51%) had a markedly reduced expression, and 45 cases (49%) showed a normal or slightly reduced expression. A statistically significant association between low HIN-1 mRNA levels and T status was observed (P = 0.036). Univariate survival curves, estimated using the method of Kaplan-Meier, defined a significant association between HIN-1 expression and both overall survival (P = 0.0095) and disease-free survival (P = 0.0122). A multivariate analysis, performed by Cox's proportional hazards regression model, confirmed that a low HIN-1 expression was the only significant factor to predict poor prognosis.

Conclusions: Our data indicate that HIN-1 expression, measured by real-time reverse transcription-PCR, is a possible prognostic factor in patients with stage I NSCLC. Additional studies are required to further validate this potential prognostic marker.

PubMed Disclaimer

Cited by

Survival prediction of stage I lung adenocarcinomas by expression of 10 genes.
Bianchi F, Nuciforo P, Vecchi M, Bernard L, Tizzoni L, Marchetti A, Buttitta F, Felicioni L, Nicassio F, Di Fiore PP. Bianchi F, et al. J Clin Invest. 2007 Nov;117(11):3436-44. doi: 10.1172/JCI32007. J Clin Invest. 2007. PMID: 17948124 Free PMC article.
Characterizing the impact of smoking and lung cancer on the airway transcriptome using RNA-Seq.
Beane J, Vick J, Schembri F, Anderlind C, Gower A, Campbell J, Luo L, Zhang XH, Xiao J, Alekseyev YO, Wang S, Levy S, Massion PP, Lenburg M, Spira A. Beane J, et al. Cancer Prev Res (Phila). 2011 Jun;4(6):803-17. doi: 10.1158/1940-6207.CAPR-11-0212. Cancer Prev Res (Phila). 2011. PMID: 21636547 Free PMC article.
Promoter methylation status of HIN-1 associated with outcomes of ovarian clear cell adenocarcinoma.
Ho CM, Huang CJ, Huang CY, Wu YY, Chang SF, Cheng WF. Ho CM, et al. Mol Cancer. 2012 Aug 8;11:53. doi: 10.1186/1476-4598-11-53. Mol Cancer. 2012. PMID: 22871047 Free PMC article.
Demethylation of HIN-1 reverses paclitaxel-resistance of ovarian clear cell carcinoma through the AKT-mTOR signaling pathway.
Ho CM, Huang CJ, Huang SH, Chang SF, Cheng WF. Ho CM, et al. BMC Cancer. 2015 Oct 24;15:789. doi: 10.1186/s12885-015-1744-5. BMC Cancer. 2015. PMID: 26497956 Free PMC article.
HIN-1: a New Epigenetic Biomarker Crucial for Therapy Selection in Glioblastoma Multiforme.
Herranz M, Padín-Iruegas ME, Martínez-Lago N, Losada SA, Raña-Díez P, Vázquez EB, Carrera JJ, Antúnez JR, Ruibal A, López-López R. Herranz M, et al. Mol Neurobiol. 2016 Apr;53(3):1802-1807. doi: 10.1007/s12035-015-9127-0. Epub 2015 Mar 11. Mol Neurobiol. 2016. PMID: 25752997

Down regulation of high in normal-1 (HIN-1) is a frequent event in stage I non-small cell lung cancer and correlates with poor clinical outcome - PubMed (original) (raw)